选择性抑制剂设计针对Mycobacterium结核病的提米酸合成酶使用炼化模拟
Pallav Sengupta1, Priyadarshi Satpati1
1Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India.
ACS omega
|April 21, 2025
概括
研究人员设计了新的类似药物的配体,可以选择性地抑制Mycobacterium tuberculosis (MtbThyX) 中的甲基胺酸合成酶. 连接物L2对MtbThyX具有很高的亲和力,对人体胆酸合成酶 (hThyA) 具有很低的亲和力,为新的结核病治疗提供了有希望的策略.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 结构生物学 结构生物学
背景情况:
- 乙基酸合成酶对于DNA合成至关重要,使其成为抗微生物和抗癌药物的标.
- 在基质结合和活性位点架构方面,Mycobacterium结核病甲基甲基甲酸合成酶 (MtbThyX) 与人类甲基甲酸合成酶 (hThyA) 有显著差异.
- 像FdUMP这样的现有抑制剂缺乏选择性,对hThyA比MtbThyX更有效.
研究的目的:
- 设计和评估MtbThyX.的新型选择性抑制剂.
- 为了利用MtbThyX独特的结构和化学特性,针对结核病开发有针对性的药物.
- 了解控制选择性连接体结合的原子级相互作用.
主要方法:
- 基于FdUMP的三种类似药物配体 (L1,L2,L3) 的设计,修改了沃森-克里克边缘,并结合了/碳酸组.
- 炼化自由能模拟用于预测设计联体对MtbThyX和hThyA的结合亲和力.
- 分析蛋白质 - 连接物相互作用,包括结,静电相互作用和水分子参与.
主要成果:
- 设计的配体显示出强烈的优先结合MtbThyX超过hThyA,正如模拟所预测的那样.
- 干L2对MtbThyX表现出最高的亲和力,对hThyA的亲和力最小.
- MtbThyX的相对干燥的活性部位有利于紧的配体构造和强大的静电相互作用,与观察到的hThyA.受损结合不同.
结论:
- 设计的配体,特别是L2,代表了一种有前途的选择性MtbThyX抑制剂的新类.
- MtbThyX的独特活性部位特征可以用于合理的抗结核药物设计.
- 详细的计算分析提供了对选择性蛋白质-连接体结合的原子层次见解,指导了未来的抑制剂开发.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K
Enzyme Inhibition
77.4K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.4K
Eukaryotic Transcription Inhibitors
9.7K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.7K
Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K


